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Abstract
Adult’s mastocytosis is usually associated with persistent systemic involvement and c-kit 816 mutation, while pediatrics
disease is mostly limited to the skin and often resolves spontaneously. We prospectively included 142 adult patients with
histologically proven mastocytosis. We compared phenotypic and genotypic features of adults patients whose disease
started during childhood (Group 1, n=28) with those of patients whose disease started at adult’s age (Group 2, n=114).
Genotypic analysis was performed on skin biopsy by sequencing of c-kit exons 17 and 8 to 13. According to WHO
classification, the percentage of systemic disease was similar (75 vs. 73%) in 2 groups. C-kit 816 mutation was found in 42%
and 77% of patients in groups 1 and 2, respectively (p,0.001). 816 c-kit mutation was associated with systemic mastocytosis
in group 2 (87% of patients with systemic mastocytosis vs. 45% with cutaneous mastocytosis, p=0.0001). Other c-kit
activating mutations were found in 23% of patients with mastocytosis’ onset before the age of 5, 0% between 6 and
15 years and 2% at adults’ age (p,0.001). In conclusion, pathogenesis of mastocytosis significantly differs according to the
age of disease’s onset. Our data may have major therapeutic relevance when considering c-kit-targeted therapy.
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Introduction
Mastocytosis is a heterogeneous disease characterized by mast
cell accumulation in various organs. Some cases are complicated
with organ insufficiency and/or symptoms due either to mast cell
infiltration or mediators release. Tissues that are commonly
involved are skin, bone marrow, gastrointestinal tract, liver and
skeletal systems[1]. The majority of mastocytosis cases occur in
children (65%)[2], mostly as isolated cutaneous forms while less
than 20% are complicated by a systemic dissemination[3]. Most of
the cases resolve by puberty[3]. In contrast, patients with
mastocytosis starting at the adult’s age present more often
persistent systemic involvement.
Stem cell factor (SCF) is the major growth factor for mast cell
survival and differentiation and interacts with its cognate receptor
KIT, a tyrosine kinase encoded by the c-kit gene. C-kit proto-
oncogene activation results in mastocytes accumulation and
abnormal migration and activation in various tissues[4,5]. In
neoplastic mast cell lines, valine or tyrosine substitution for an
aspartate in c-kit codon 816 results in constitutive phosphorylation
and activation of KIT[6]. In early reports, Asp816Val was found
in peripheral blood of 27% of 55 adult patients with mastocytosis
mainly of systemic forms or associated with clonal haematological
disorders [7–9]. Currently, it is well admitted that this mutation
was also reported in skin and bone marrow in the vast majority of
adult patients with systemic or cutaneous mastocytosis[7–11]. In
contrast, mutations in the c-kit gene are considered as rare in
children[7–10]. However, a recent study reports presence of 816
mutations in 11 out of 13 adults with the pediatric onset of
cutaneous mastocytosis and in all children with systemic
mastocytosis (SM)[12]. Taken together these findings may explain
differences in clinical presentation and outcome according to age
of onset, and particularly the resolution of the disease in children’s
mastocytosis. The finding of these mutations may have important
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therapeutics particularly regarding the potential use of c-kit
inhibitors.
To our knowledge, no large study has attempted to describe
characteristics of adult’s mastocytosis according to the age of
disease’s onset. In this report, we compared phenotype and c-kit
genotype in a large prospective cohort of adults’ patients with
histologically confirmed mastocytosis according to their childhood
or adulthood age of onset.
Results
A hundred and forty-two patients with mastocytosis were
recruited, 28 patients in group 1 (13 in group 1A and 15 in group
1B) and 114 in group 2. For the whole population, thirty-five
percent were male, with a mean age of 46614 years at the time of
inclusion. Seventy-three percent had histologically confirmed
(bone marrow or other histologically proven organ involvement)
systemic mastocytosis (SM) with 63% ISM, 6% ASM, 3% SSM
and 1% SM-ASHNMD. The most frequently involved organ was
bone marrow, concerning 64% of the patients, then skeletal system
(40%), gastrointestinal system (12%) and liver (4%). Considering
skin lesions, 90% of the patients presented with urticaria
pigmentosa, 27% with diffuse cutaneous mastocytosis, and 14%
with TEMP. Clinical examination showed hepatomegaly for 12%
patients, splenomegaly for 9% and adenomegaly for 7%. The most
frequent symptoms were asthenia (65% of the patients), flush
(56%), diarrhoea (50%), abdominal pain (47%), skeletal pain
(43%), and anaphylactic shock or blackout (17%). Tryptase level
was above 20 ng/ml for 65% of the patients.
Comparison of patients’ characteristics between groups 1 and 2 is
reported in table 1. As expected patients whose disease started in
adulthood had a shorter duration of mastocytosis evolution. Patients
with childhood onset mastocytosis had less frequent serum tryptase
elevation and tended to present more frequent liver involvement.
Gender, presence of systemic involvement, type of skin lesion, bone
marrow infiltration, gastrointestinal involvement, hepatomegaly,
splenomegaly, adenomegaly, weakness, anaphylactoid shock or
blackout, nausea, abdominal pain, diarrhea, osteoporosis and
prevalence of X-ray bone lesions did not statistically differ between
two groups. Hematological and liver biological parameters did not
differ according to the age of onset (data not shown). Familial
mastocytosis was found in 12 patients (8%).
Genotypic characteristics of patients are reported in table 2.
Sixty eight percent of the patients presented a D816X mutation of
c-kit gene in the exon number 17. Patients with an adult onset
mastocytosis had more frequently D816X c-kit mutation (77% in
group 2 vs. 42% of patients in group 1, p,0.001). Elevated
tryptase serum levels (.20 ng/ml) were more frequently observed
in the group of patients with the presence of 816 c-kit mutation
(88%) vs those without (44%) (p,0.0001). Presence of D816X c-kit
mutation was not associated with duration of mastocytosis
evolution (16.25612.25 years in patients without mutation vs.
14611.65 in patients with the mutation, p=0.328).
Mutation screening from exons 8 through 13 was performed for
816 wild type patients except 1 patient in group 1A, 1 patient in
group 1B and 2 in group 2 because the amount of RNA was not
sufficient and a new biopsy was denied. Non-816 mutations were
Table 1. Characteristics of 142 adults with mastocytosis
according to their age of onset.
Age of onset
Group 1:
#15 years
(n=28)
Group 2:
.15 years
(n=114) P
N( % ) N( % )
Females 19 (68) 74 (65) 0.700
Age 32610 49613 ,0.0001
Age of onset 7663 6 613 ,0.0001
Duration of mastocytosis evolution
(years)
25613 13611 ,0.0001
WHO classification
CM 7 (25) 31 (27)
ISM 17 (60) 72 (63)
ASM 3 (11) 6 (5)
SSM 1 (3) 3 (3)
SM-AHNMD 0 (0) 2 (2) 0.820
SM 21 (75) 83 (73) 0.800
Hepatomegaly 5 (15) 14 (11) 0.524
Splenomegaly 4 (12) 10 (8) 0.459
Adenomegaly 1 (8) 7 (7) 0.890
Clinical cutaneous form
Urticaria pigmentosa 24 (86) 104 (91) 0.381
Diffuse cutaneous mastocytosis 6 (21) 32 (33) 0.316
TMEP 4 (14) 13 (14) 0.841
Organ involvement
Gastrointestinal 5 (18) 12 (11) 0.284
Bone marrow 16 (57) 75 (68) 0.414
Liver 3 (11) 3 (3) 0.058
Skeletal involvement 11 (39) 47 (41) 0.839
Systemic symptoms
Flush 19 (68) 60 (54) 0.188
Weakness 15 (54) 71 (67) 0.188
Anaphylactoid shock 7 (26) 17 (13) 0.200
Abdominal pain 15 (54) 47 (46) 0.456
Diarrhoea 12 (43) 56 (52) 0.396
Nausea 6 (26) 12 (26) 1.000
Skeletal pain 15 (54) 42 (40) 0.184
Elevated tryptase serum levels
(.20 ng/ml)
12 (48) 70 (69) 0.045
CM: cutaneous mastocytosis, ISM: indolent systemic mastocytosis, ASM:
aggressive systemic mastocytosis, SSM: smouldering systemic matocytosis, SM-
AHNMD: systemic mastocytosis with an associated haematological clonal non-
mast cell lineage disease, TMPE: telangiectasia macularis eruptive perstans.
doi:10.1371/journal.pone.0001906.t001
Table 2. Exons 8 through 13 and 17 mutations according to
mastocytosis age of onset.
Age of onset WT Other mutations Mut 816
Group 1A (n=12) 3 (25) 3 (25) 6 (50)
Group 1B (n=14) 9 (64) 0 (0) 5 (36)
Group 2 (n=112) 24 (21) 2 (2) 86 (77)
Data are expressed in number (percentage), 816: substitution of valine in 816
codon of c-kit, Other mutations: mutation in exons 8 through 13. WT: absence
of mutation in exons 8 through 13 and 17. Complete genotype was not
available for 4 816 WT patients; 1 patient in group 1A, 1 in group 1B and 2 in
group 2.
doi:10.1371/journal.pone.0001906.t002
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2% in group 2, p=0.002). In group 1A, 2 patients presented with
Del419Ddeletioninexon8and1withK509Imutationinexon9.In
group 2, 1 patient presented Del419D deletion in exon 8 and 1
patient with V560G mutation in exon 11. We report the main
characteristicsofthesepatientswithunusualc-kitmutationsintable3.
We studied the association between genotype and phenotype in
groups 1 and 2, respectively (table 4). No association between
genotype and mastocytosis form according to the WHO
classification were evidenced in group 1, 71% vs 57% were
mutated for 816ckit in CM and SM repectively. In contrast, SM
was strongly associated with D816 c-kit mutation in group 2, 87%
vs. 45% presented 816 mutation in SM and CM, respectively. In
patients with SM, presence of 816 c kit mutation was associated
with adult mastocytosis onset (87% vs. 43% in group 2 and 1,
respectively, p,0.001).
Discussion
It is currently admitted that pediatrics and adult is mastocytosis
exhibit different clinical and genotypic features[2]. To our
knowledge, however, only one retrospective study has compared
phenotypic characteristics of mastocytosis according to the age of
onset [16]. The authors reported more often significant clinical
improvement and more frequent gastrointestinal symptoms in
childhood onset patients. However, patient’s age was unknown,
the search for systemic involvement was not investigated in all
cases and a long-term follow up was available only for a subgroup
of patients.
In the present report, we have demonstrated that although
exhibiting genotypic differences, clinical features of adult patients
with mastocytosis were similar regardless their adult or pediatric
onset.
Overall the percentage of SM was 73% and rates of SM did not
differ according to the age of onset. In previous reports, SM was
reported to be more frequent in adult mastocytosis patients than in
children with mastocytosis, regardless of their outcome. Worobec
et al. reported 65 patients with mastocytosis; 90% of the 55 adults
studied presented SM, whereas only 30% of the 10 children
studied presented SM [7]. In agreement with those findings,
previous reports have also shown that bone marrow involvement
was significantly more frequent in adult (45%–90%)[17] [18] than
in pediatric (18%) [19] patients. These discrepancies with the
results of our study might be explained by the fact that pediatric
patients with systemic involvement may not resolve at puberty and
therefore may not differ from mastocytosis beginning at adult’s
age. Alternatively, adult patients with mastocytosis related to
pediatric onset may have evolved from a cutaneous to a systemic
disease because of the longer course of the disease. However, this
hypothesis is unlikely since tryptase levels, a marker of mast cell
burden, was significantly lower in the group 1.
Our work elucidated that c-kit genotype differed with the age of
mastocytosis onset. D816X mutation in exon 17 of c-kit was more
frequent in patients with adult onset mastocytosis than in those
with childhood onset. No large previous study had compared c-kit
genotype in mastocytosis according to age of onset. However,
several studies compared c-kit genotype in adults and children
patients with mastocytosis. Most of the studies reported a higher
prevalence of D816X c-kit mutations in adults than in children
with mastocytosis. Longley et al. reported that all of 10 adult
patients (with adult onset) with cutaneous or systemic mastocytosis
presented D816 mutation on skin biopsy, whereas only 13% of the
15 children with mastocytosis age of onset between 0 and 12 years
had the mutation [9]. In another study, 816 mutation was present
in skin for 6 out of 6 adults patients with adult onset (5 patients
with SM and 1 with CM), and none of the 11 children patients
with CM[10]. A recent study reported 93% of D816V c-kit mutation
in bone marrow of 113 adult patients with systemic mastocytosis,
however, no data on skin biopsy and age of disease’s onset was
availableinthisstudy[20].Overallthesestudiessuggestthat816 c-kit
mutation prevalence is high in adult patients and low in pediatrics
patients. However, Yanagihori et al reported D816X c-kit mutation
for 11 out of 13 adults with CM in whom disease started during
infancy [12]. In line with this report, in our study we found that 816
mutations was higher (40%) than expected in the population of
adults patients with pediatric onset. These findings strongly suggest
that 816 mutations in pediatric patients may be associated to a
higher probability of persistence at adult age.
Here, non-816 c-kit mutations were rarely found in adults’ onset
patients (2%), whereas it represented 25% of patients with age of
onset below 5 years old and 0% of patients with an age of onset
between 5 and 15 years. We studied exons 17 and 8 through 13
but not the whole c-kit gene because a previous study of our group
targeted the entire gene in 50 children and did not find any
mutation in other exons of c-kit gene (unpublished personal data).
Three patients presented Del419D in exon 8 of c-kit, 2 patients had
a disease onset before the age of 5 and 1 after 15, all presented SM
including one with gastrointestinal involvement. This mutation
Table 3. Description of 5 adult patients with mastocytosis not related to 816 c-kit mutation.
Mutation Exon Gender Age of onset WHO classification Familial form
K509I 9 M ,1 year CM No
Del419D 8 M ,1 year ISM (bone marrow) No
Del419D 8 F 5 years ISM (bone marrow) No
Del419D 8 F 41 years ISM (bone marrow, gastrointestinal) No
V560G 11 F 53 years CM No
doi:10.1371/journal.pone.0001906.t003
Table 4. Relationship between phenotype and genotype in
patients with mastocytosis according to their age of onset.
WHO classification Group 1 Group 2
wt816 mut 816 wt816 mut 816
CM (n=38) 5 (71) 2 (29) 17 (55) 14 (45) p=0.788
SM (n=104) 12 (57) 9 (43) 11 (13) 72 (87) p,0.001
p=0.668 p,0.001
Data are expressed in number (percentage).
doi:10.1371/journal.pone.0001906.t004
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gastrointestinal stromal tumor and mastocytosis [21]. In the case
reported here, the mutation was not found in peripheral blood
mononuclear cells, ruling out a germinal mutation. One of our
patients with nonfamilial CM from group 1A presented a K509I
mutation in exon 9. Another recent study reported K509I
mutation in a case of familial mastocytosis [22]. An adult onset
patient with CM/ISM presented V560G mutation in exon11,
which has previously been reported in 2 adults, 1 CM and 1 SM
[10]. Taken together, these results suggest that in pediatric patients
below the age of 15 other mutations than the classical 816 of the c-
kit gene may occur. Therefore, pathogenesis of mastocytosis clearly
differs according to age’s onset.
Prospective studies in pediatric population is currently per-
formed to determine whether frequency of these unusual
mutations might be a pronostic indicator.
In conclusion, despite similar clinical presentation, the high
frequency of non mutated c-kit gene in case of childhood’s onset
contrasted with a high frequency of 816 mutation in mastocytosis
cases starting at the adult’s age. These findings may have
important therapeutic implications when targeted therapy against
kinase activity of c-kit is considered.
Methods
Patients
Adult patients (.18 years old) with mastocytosis were recruited
prospectively through the French mastocytosis network (AFIRMM
« French Association for the Initiatives of Research on Mastocyte
and Mastocytosis», protocol ‘‘Physiopathological and clinical study
of mastocytosis in adult patients’’) to compare phenotypic and
genotypic features of patients according to their age of onset. Data
collection was conducted in 15 medical centers between January
2000 and December 2004.
Patients were included after written informed consent was
obtained. The study was approved by the ethical committee of
Pitie-Salpetrie `re university hospital (Paris, France) and data were
computerized in accordance with the French Commission Informa-
tique et Liberte ´s. All patients had a histologically proven mastocytosis.
In all cases skin biopsies and bone marrow biopsies/or aspiration
were performed. The diagnosis of cutaneous involvement by
mastocytosis was based on the association of both clinical symptoms
compatible with cutaneous mastocytosis and the presence of a mast
cells multifocal accumulation in skin biopsy according to usual
histopathological criteria[13,14]. In most of the cases TMEP doesn’t
show a significant increase in mast cells and the diagnosis was made
in association with clinical datas. However, some subtle features can
be useful in the histological diagnosis such as a slight increased
number of fusiform and loosely arranged mast cells situated around
dilated superficial capillaries. Immunohistochemistry with anti-
CD25 was performed on thirty mastocytosis skin samples out of
this series, including all various forms of cutaneous mastocytosis,
such as urticaria pigmentosa, TMEP and systemic mastocytosis with
skin involvement. All cases were negative.
Bone marrow involvement was defined by bone marrow
aspiration and/or biopsy with a dense focal or diffuse mast cell
infiltrate with spindle-shaped cells [15]. However, in several cases,
foci of spindle mast cells located mainly around blood vessels or
bone trabeculae were observed which allowed the bone marrow to
be classified as involved. Mast cells expressed CD117 and tryptase
but in our hands, were rarely stained with CD25 antibody, but
were usually closely associated with foci of small B and T-cells.
Liver and/or gastrointestinal involvements were histologically
proven. The presence of mast cells within the sinusoids defined
liver involvement and the presence of a dense mast cells infiltrate
in lamina propria defined gastrointestinal involvement [15].
Clinical, biological and histological data were recorded through
a Clinical Records Form (CRF). The following criteria were
collected: age at data collection, age of onset of cutaneous
involvement based on available written medical reports from a
pediatrician or patient’s parents, age at diagnosis, gender,
cutaneous clinical form (mastocytoma, urticaria pigmentosa,
telangiectasia macularis eruptiva perstans (TMEP)), flush, fatigue,
anaphylactoid shock, abdominal pain, diarrhea, presence of SM
and date of onset, hepatomegaly, splenomegaly, adenomegaly,
bone pain, osteoporosis (defined as T score ,22), radiographic
skeletal lesion, the presence of bone marrow involvement on bone
marrow aspiration and/or biopsy, gastrointestinal, liver involve-
ment, blood cell count, liver enzymes and tryptase serum levels.
Bone involvement included osteoporosis and/or compatible
radiological bone lesions. Patients were classified according to
WHO classification [1], in CM, indolent systemic mastocytosis
(ISM), smouldering systemic matocytosis (SSM), aggressive
systemic mastocytosis (ASM) or systemic mastocytosis with an
associated haematological clonal non-mast cell lineage disease
(SM-AHNMD). In cases in which bone marrow aspirate and/or
biopsy did not disclose mast cell involvement and that no other
histologically organ involvement was proven (liver, gastrointestinal
tract), patients were considered to have CM. Group 1 included
patients with mastocytosis age of onset #15 years old (because this
corresponds to the cut off between pediatrics and adult’s
population in the French health system). This group was divided
in group 1A that included patients with age of onset #5 years old
and group 1B .5 and #15 years old. Group 2 included patients
with mastocytosis age of onset .15 years old.
Mutation screening
Skin samples. A skin biopsy of 3 to 4 mm on mastocytosis
cutaneous lesions was performed for each patient and directly
incubated in RNA later (Qiagen) by the dermatologist in charge of
the patient before sending it for centralization to the reference
laboratory. Skin biopsy was systematically performed at inclusion
in this study, therefore at various times from initial mastocytosis
diagnosis. We previously assessed that nucleic acids in biopsies
were stable for one week at room temperature (data not shown).
Samples were stored at 280uC in such buffer upon arrival.
RNA preparation and c-kit D816V mutation detec-
tion. Total RNA was extracted from skin biopsies using the
Rneasy mini kit (Qiagen). Complementary DNA was synthesised by
using random hexamers and oligo dT as oligonucleotide primer
from 200 ng total RNA using the stratascript first-strand synthesis
system (Stratagene) in a total volume of 50 ml as recommended by
the manufacturer. Then, 2.5 ml of cDNA was introduced in each
polymerase chain reaction (PCR).
c-kit gene was amplified by PCR using HotStartTaq
TM DNA
polymerase (Qiagen S.A. France). A total of 40 cycles was
performed using either the 9700 or 2700 Gene Amp PCR Systems
(Applied biosystems) at 94uC for 30 sec, 57uC for 30 sec and 72uC
for 45 sec.
c-Kit coding sequences were amplified from complementary
DNA with the PCR by using primer pairs indicated in table 1. For
the specific detection of the mutation at the 816 position, we used
the primer pairs (2295s & 2661r) indicated in table 5.
Direct amplimer sequencing was carried out after PCR
products were purified with the multiscreen HTS MNSV030050
purification system, (Millipore, Guyancourt France). They were
directly sequenced with Big dye terminator V 1.1 (Applied
biosystems) on an ABI Prism 3130 sequencer (Applied biosystems)
Mastocytosis and Age of Onset
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using 2295s & 2647r sequencing primers described in table 5.
Confirmation of D816 mutation detection. D
816V
mutation was also confirmed by restriction digest analysis with
BsmA1 and Ple1 restriction enzymes, which detect wild type and
mutated form, respectively. Purified fluorescent primers (2295sF &
2661rF; see table 1) were used for PCR reactions. Size of
restriction digest fragments (201 for Bsma1 fragment and 179 and
187 for Ple1 fragment) were directly determined on a 16 capillary
sequencer (ABI Prism 3130 sequencer) with the GeneMapper
software (Applied biosystems) by comparison with size of the
Genescan rox 500 markers (Applied biosystems).
Confirmation of the lack of 816 mutation. In the case of
detection of a WT sequence, an independent PCR was performed
on cDNA. Same conditions as described above were used for the
PCR reaction, except that 30 cycles were used. Then, PCR
products were digested by BsmaI enzyme in order to increase a
putative mutated signal. The Bsma1 digested products were then
amplified in a 25 cycles nested-PCR reaction using 2341s and
2600r primer pairs (see table 5). Same conditions of temperature
and time as above were applied for this reaction. Purified nested
PCR products were then sequenced with 2341s and 2600r primer
pairs as described above and analysed with the Seqscape software.
Exons 8 through 13 c-kit coding regions were sequenced
for WT
816 patients. A PCR, using the same conditions, was
performed on cDNA except that the c-Kit coding region was
separated in five different fragments (PCRK1 to K5) for PCR
reaction described in table 5. Each PCR fragment was then
sequenced as described above using sequencing primer described
in table 5.
Statistical analysis
Statistical analyses were performed using SAS version 9.1 and
Excel.
Quantitative variables were summarized using the following
descriptive statistics: number of observed and missing data, mean,
standard deviation, median, minimum and maximum. Absolute
and relative frequency distributions were provided for qualitative
variables. We used Student’ s T test for continuous variables with
limited effectives, and the Wilcoxon test for the nonparametric
values. We confronted the values. For the discontinuous values, we
used the chi2 test or Fisher’s exact test. Statistical significance was
defined as p value,0.05.
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doi:10.1371/journal.pone.0001906.t005
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